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ORIGINAL ARTICLE  
VITAMIN-D TOXICITY AND OTHER NON-MALIGNANT CAUSES OF 
HYPERCALCEMIA: A RETROSPECTIVE STUDY AT A TERTIARY 
CARE HOSPITAL IN PAKISTAN 
Muhammad Naeem Khan, Muhammad Qamar Masood*, Mohammad Arsalan Siddiqui**, 
Sabahat Naz*, Najmul Islam* 
Department Diabetes Endocrinology & Metabolism, Liaquat National Hospital and Medical College, Karachi, *Aga Khan University Hospital 
Karachi, **Dow Medical College Karachi-Pakistan 
Background: Hypercalcemia is a common clinical problem; primary hyperparathyroidism and 
malignancy is commonest causes of hypercalcemia. Aetiology of hypercalcemia are changing, 
causes that were diseases of the past like Vitamin-D toxicity and milk alkali syndrome are 
observed more often. Vitamin-D deficiency is an important problem and overzealous replacement 
of Vitamin-D has been observed, suspected to cause toxicity. Method: This was a retrospective 
review of patients admitted at the Aga Khan University Hospital from January 2008 to December 
2013 with hypercalcemia. We reviewed the electronic health records for laboratory and 
radiological studies, and discharge summaries to establish the cause of hypercalcemia. Patients 
with solid tumour malignancy were excluded from the analysis. The treatment records and hospital 
course of patients diagnosed with Vitamin-D toxicity were also reviewed. Results: Primary 
hyperparathyroidism was the most common cause of hypercalcemia comprising 41 (28.2 %) 
patients. Vitamin-D toxicity was present in 25 (17.3%) and probable Vitamin-D toxicity 11 (7.6 
%) inpatients. Vitamin-D toxicity and probable Vitamin-D toxicity together comprised 36 (24.8%) 
cases. Other causes of hypercalcemia included multiple myeloma 18 (12.4%) patients, tuberculosis 
6 (4.1%) patients, chronic kidney disease6 (4.1%) cases, sarcoidosis 4 (2.7%) and lymphoma 3 
(2.0%) patients. In 29(20%) patients a cause of hypercalcemia could not be determined and were 
labelled as undiagnosed cases. Conclusion: Vitamin-D toxicity was the second commonest cause 
of hypercalcemia after primary hyperparathyroidism. Knowledge of the prevalent and emerging 
causes of hypercalcemia is important for prompt diagnosis and treatment.  
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INTRODUCTION 
Hypocalcaemia is a common clinical problem; 
primary hyperparathyroidism (HPT) and malignancy 
are commonest causes of hypercalcemia.1,2 
Frequency of hypercalcemia in different disease 
entities has been described. However recent literature 
is lacking about frequency of different aetiologies 
when patient presents primarily with hypercalcemia. 
Study in the military veteran’s population in the 
United States showed that 54% of the patients had 
hypercalcemia attributable to causes other than 
malignant disease or HPT.3 
Studies in our region are limited to the 
frequency of hypercalcemia occurring in specific 
diseases. The spectrum of the aetiology of 
hypercalcemia may be changing and the causes that 
were diseases of the past like Vitamin-D toxicity 
(VDT) and milk alkali syndrome; are observed more 
often. The only study highlighting the frequency of 
hypercalcemia in Pakistan is limited to patients with 
multiple myeloma.4  
Vitamin-D deficiency (VDD) has resurfaced 
as an important public health problem; and at the 
same time overzealous replacement of Vitamin-D has 
also been observed. Intramuscular Vitamin-D 
preparations, containing 200,000 and 600,000 IU 
of Vitamin-D3 are commonly used in Pakistan. 
Guidelines on these vitamin preparations are 
lacking. Practices among physicians vary widely, 
conservative being using 600,000 IU IM or orally 
every 3 months to very aggressive regimen of 
600,000 IU weekly for up to 12 weeks.5 Review of 
laboratory data from our centre is suggesting 
shifting of Vitamin-D deficiency to 
hypervitaminosis D and toxicity.6 Sporadic cases 
of VDT have been noticed by the physician 
community. However, there is no published 
literature to evaluate the magnitude of VDT. 
Bansal et al from India reported a case of Vitamin-
D toxicity in a patient who had received 10 
injections of Vitamin-D3, 600,000IU after the knee 
surgery.7 Hypercalcemia has also been reported 
because of excess ingestion of Vitamin-D in 
dietary supplements.8,10 In two cases, the amounts 
of Vitamin-D found in vitamin preparations were 
much higher than listed by the manufacturer.9,10  
Hypercalcemia presents as a diagnostic 
challenge except in patients with solid tumour 
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malignancy where it is a late finding and 
underlying disease is often known.11 Knowledge of 
the commonly occurring causes will help in 
reaching the diagnosis promptly and in a cost-
effective manner. It can identify preventable 
causes and may demand change in replacement 
practices of Vitamin-D.  
MATERIAL AND METHODS 
This study was a retrospective analysis examining 
the causes of hypercalcemia in patients without 
solid tumour malignancy. A list of patients, 
admitted with hypercalcemia from January 2008 to 
December 2013 at the Aga Khan University 
Hospital (AKUH) was generated by Health 
Information Management Systems department. 
Patients admitted under the care of an oncologist 
were excluded from the search. The study was 
approved by the ethics review committee of 
AKUH.  
The electronic health records were 
reviewed for laboratory studies including 
histopathology, radiological investigations and 
discharge summaries to establish the cause of 
hypercalcemia. Treatment records and hospital 
course of patients diagnosed with VDT were 
reviewed.  
Hypercalcemia was labelled if there were 
2 or more readings of serum calcium (Ca) or 
albumin corrected calcium level above 10.2 mg/dl. 
Primary HPT was diagnosed if there was 
unequivocal hypercalcemia and high or 
inappropriately normal intact parathyroid hormone 
(iPTH) levels. VDT was diagnosed in patients with 
hypercalcemia and 25-hydroxy Vitamin-D (25-
OHD) >150 ng/ml and low iPTH. Probable 
Vitamin-D toxicity (probable VDT) was labelled in 
patients with high Ca, suppressed iPTH and 25-
OHD level between 80–149 ng/ml and no other 
cause of hypercalcemia. The diagnosis of multiple 
myeloma was based on immunofixation or bone 
marrow aspiration studies. The diagnoses of 
tuberculosis, sarcoidosis and lymphoma were made 
on review of histopathology, microbiology and 
radiological studies. The aetiology once 
established was reconfirmed by a second 
researcher. In patients where review of medical 
records did not reveal any diagnosis or workup 
was incomplete were referred to as undiagnosed 
cases.  
Data was collected on patient demographics, 
age, sex, serum Ca, serum phosphorus, serum iPTH, 
25-OHD, urine creatinine, urine Ca, blood urea 
nitrogen, clinical notes, surgical interventions, 
pathology reports, and radiologic reports. Complete 
details were recorded on a proforma. 
All analyses were conducted by using the SPSS-19.0. 
A descriptive analysis was done and features were 
presented as mean±standard deviation for 
quantitative variables and number (Percentage) for 
qualitative variables. 
RESULTS 
Health information system generated a list of 322 
patients with hypercalcemia. Review of the records 
revealed that 36 patients had normal serum Ca levels 
and 28 patients had transient hypercalcemia which 
did not recur during hospital stay. Out of remaining 
258 patients 113 patients had solid tumour and were 
excluded from further analysis.  
The electronic health records of remaining 
145 patients were analysed to establish the aetiology 
of hypercalcemia. This included 100 females (69%) 
and 45 males (31%), with the mean age of 
64.5±13.16 and mean Ca13.16±1.88 mg/dl.  
HPT was the most common cause of 
hypercalcemia comprising 41 (28.3 %) patients. In 
these patients female to male ratio was 3.5:1 with 
mean PTH level of 638.1±762.1 pg/ml, mean calcium 
level 12.8±2.2 mg/dl. 
Twenty-five (17.3%) had VDT; female to 
male ratio in these patients was 2.1:1. The mean Ca 
was 13.5±1.6 mg/dl.  The mean 25-OHD level in four 
patients was 368 ng/ml and in remaining 21 patients 
it was reported as >150 ng/ml. Drowsiness was the 
most common clinical presentation. The average 
hospital stay was 7 days and 2 patients died during 
hospitalization. The cause of death in one patient was 
aspiration pneumonia and Non-ST elevation 
myocardial infarction developed during hospital 
course. The other patient had prolonged hospital stay 
in two hospitals and had infected bedsores with 
resultant septic shock as the cause of death. These 
patients underwent extensive work up for drowsiness 
including magnetic resonance imaging (MRI) brain, 
cerebrospinal fluid analysis and 
electroencephalogram. The diagnosis was evident by 
the 3rd day of hospital stay and required multiple tests 
including iPTH, 25-OHD, serum protein 
electrophoresis, and angiotensin converting enzyme 
levels in some cases. History of administration of 
multiple injections of high doses (600,000 units) of 
Vitamin-D3 was available in half of the patients. It 
was prescribed for osteoporosis; osteoporosis related 
fractures and generalized body pain. Hypercalcemia 
was managed with administration of intravenous 
normal saline, furosemide and pamidronate. 
Subcutaneous calcitonin and oral prednisolone was 
used in some cases.  The hypercalcemia was 
corrected after 3 days of the administration of 
pamidronate. The dose ranged from 30 to 90 mg. One 
patient needed a second dose of pamidronate.  
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In addition, 11 (7.6 %) patients had probable VDT. 
Female to male ratio was 2.6:1. Mean 25-OHD level 
was 92.7±16.1 ng/ml and mean Ca was 12.5±1.8 
mg/dl. These patients had similar clinical 
presentation and clinical course. One patient died in 
this group, who was intubated because of low 
conscious level secondary to hypercalcemia, had 
prolonged hospital stay and multiple hospital 
acquired infections.  
Other causes of hypercalcemia included 
multiple myeloma 18 (12.4%) patients, tuberculosis 6 
(4.1%) patients, Chronic kidney disease 6 (4.1%) 
cases, sarcoidosis 4 (2.7%) and lymphoma 3 (2.0%) 
patients. In 29 (20%) patients a cause of 
hypercalcemia could not be ascertained and were 
labelled as undiagnosed cases. These patients had a 
PTH independent cause of hypercalcemia. However 
further workup was not available to reach to a 
definitive diagnosis. In one patient 
paraphenylenediamine poisoning was the cause of 
hypercalcemia. The frequencies of different causes 
with relative gender distribution are shown in table-1.  
VDT and probable VDT together comprised 
36 (24.8%) of the cases and one patient with HPT 
had 25-OHD in toxic range. Table-2 mentions the 
mean values of Ca, PTH and 25-OHD in various 
causes of hypercalcemia.  
 
Table-1: Frequency and gender distribution of different causes of hypercalcemia 
  Male Female Total 
 45 (31%) 100 (69%) 145 
Hyperparathyroidism 9 (20) 32 (32) 41 (28.3) 
Undiagnosed cases 8 (17.8) 21 (21) 29 (20) 
Vitamin-D toxicity 8 (17.8) 17 (17) 25 (17.2) 
Multiple myeloma 7 (15.6) 11 (11) 18 (12.4) 
Probable Vitamin-D toxicity 3 (6.7) 8 (8) 11 (7.6) 
Tuberculosis 4 (8.9) 2 (2) 6 (4.1) 
Chronic kidney disease 3 (6.7) 3 (3) 6 (4.1) 
Sarcoidosis 1 (2.2) 3 (3) 4 (2.8) 
Lymphoma 2 (4.) 1 (1) 3 (2.1) 
Hyperparathyroidism with Vitamin-D toxicity 0 (0) 1 (1) 1 (0.7) 
Miscellaneous 0 (0) 1 (1) 1 (0.7) 
Table-2: Mean values of PTH, Vitamin-D and Calcium 
 Total (n=145) PTH (pg/ml) Vitamin-D (ng/ml) Calcium (mg/dl) 
Hyperparathyroidism (n=41) 638.1±762.1 48.8±84 12.8±2.2 
Vitamin-D toxicity (n=25) 8.3±8.7 184.8±129.4 13.5±1.6 
Probable Vitamin-D toxicity (n=11) 12.1±7.8 92.7±16.1 12.5±1.8 
Undiagnosed cases (n=29) 7.6±6.7 37.5±19.2 13.5±1.8 
Multiple myeloma (n=18) 9.9±6.4 23.6±15.3 12.9±1.5 
Tuberculosis (n=6) 5.8±3.8 18.7±10 12.4±1.1 
Sarcoidosis (n=4) 6±6 23.2±7.8 13.8±1.7 
Lymphoma (n=3) 4.7±2.3 24.8±6.1 15.7 
CKD (n=6) 24.6±18.9 16.1±8.8 12.06±0.9 
HPT with Vit D toxicity (n=1) 443 150 15.1 
Miscellaneous (n=1) 7.24 6.16 14.9 
Mean±SD are reported 
 
DISCUSSION 
HPT in our data remained as one the commonest 
cause of hypercalcemia.1 Mean age and female 
preponderance of HPT patients in our study are 
similar to what reported by others.12,13 Wermer et al 
reported the peak incidence of primary 
hyperparathyroidism in the seventh decade with most 
cases occur in women.13 Primary HPT used to be 
presented as bones, stones and groans in the past. 
These days the diagnosis is generally biochemical 
with high serum calcium and elevated iPTH. Once 
biochemical diagnosis is established, localization of 
parathyroid adenoma is made by parathyroid 
scintigraphy and or by sonography by an experienced 
sinologist. Surgical removal of the parathyroid 
adenoma is the only curative therapy for primary 
HPT; however, patients above 50 years of age and 
mild hypercalcemia and no complications can be 
followed.14 
VDT has emerged as the second commonest 
cause of hypercalcemia in our study. In 25 patients 
hypercalcemia can solely be attributed to vitamin 
toxicity. The Vitamin-D was administered in the 
setting of osteoporosis, related fractures and for 
generalized weakness. The amount of Vitamin-D 
taken was documented in half of the patients. 
Multiple injections of high dose preparations were 
the main etiologic factor of VDT. The exact amount 
of Vitamin-D taken by these patients could not be 
exactly quantified because of the retrospective nature 
of the study. In most cases, it was Vitamin-D3 
600,000 IU injection given weekly for 6-8 weeks. 
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Koul et al reported 10 cases of VDT over 10 years 
from Kashmir valley with one patient died because of 
concomitant sepsis and multiorgan failure.15 These 
patients again had received Vitamin-D in form of 
multiple injections and oral sachet for back pain, 
radiculopathy, osteoarthritis and generalized 
weakness.  
Considering this overenthusiastic practice of 
Vitamin-D replacement we recently have published a 
randomized control trial comparing replacement 
strategies with oral and intramuscular doses of 
commonly used preparations. Our study showed that 
a single dose of 600,000 units of Vitamin-D3 
corrected the VDD in 94% of the participants and 
multiple injections were not required to correct the 
VDD.5 
The upper limit of 25-OHD levels has not 
been defined. Studies in lifeguards, farmers near the 
equator, and sun dwelling hunter gatherers shown 
that they maintain blood levels between 40–80 ng/ml 
on sun exposure alone.16 Marcus et al has reported a 
case of hypercalcemia in a patient with multiple 
sclerosis with 25-OHD level of 103ng/ml and no 
other identifiable cause of hypercalcemia.17 In our 
study, we have identified 11 patients with 
unequivocal hypercalcemia, low iPTH and 25-OHD 
level ranging from 80–149 pg/ml. We characterized 
them as probable Vitamin-D toxicity. Patients in this 
group exhibit significant hypercalcemia and similar 
hospital course as patients with VDT. 
Multiple Myeloma presented as third 
important cause of hypercalcemia after HPT and 
VDT. This diagnosis is generally sought very 
commonly in medical units, and in our study serum 
protein electrophoresis was done in most patients. 
Other causes of hypercalcemia in our study include 
tuberculosis, chronic kidney disease, sarcoidosis and 
lymphoma.  
The work up of hypercalcemia after the 
availability of intact PTH assays has been simplified 
into PTH dependent and independent causes. PTH 
dependent causes include Primary HPT as the 
commonest cause, and rarely prolonged lithium use, 
familial hypocalciuric hypercalcemia and tertiary 
hyperparathyroidism would result in similar 
biochemical profile. To identify a PTH independent 
cause remains a challenge when solid tumour 
malignancy is not evident. The causes of PTH 
independent hypercalcemia commonly include solid 
tumour malignancy, multiple myeloma and 
granulomatous diseases like tuberculosis, sarcoidosis 
and lymphoma.18 
Management of acute hypercalcemia is 
similar irrespective of the cause; this includes 
aggressive hydration with intravenous normal saline, 
low dose furosemide once adequate fluid 
resuscitation is achieved, and intravenous 
bisphosphonate. After initial treatment, management 
of underlying cause is important.19  
The workup or its documentation was 
insufficient in 20% of cases to reach to a conclusive 
diagnosis; this is because of the retrospective nature 
of the study and it is one of the major limitations of 
the study.  
Another limitation of our study is that we 
had not reviewed the management of causes of 
hypercalcemia other than VDT in detail. This is 
because the causes are varied and requires specific 
treatment.  
CONCLUSION 
Prompt identification and treatment of VDT is very 
important because of associated significant morbidity 
and mortality, prolonged hospital and costly 
investigations. VDT should be kept in mind in cases 
of PTH independent hypercalcemia, history of 
Vitamin-D intake should be sought and prompt 
treatment with hydration and intravenous 
bisphosphonates should be initiated. In one patient 
who died because of hospital acquired infections had 
a prolonged hospital stay and had undergone multiple 
investigations including bone marrow examination 
and trephine to evaluate the cause of hypercalcemia.  
Physician education regarding replacement 
of Vitamin-D is of utmost importance as inadvertent 
administration remains the main cause of toxicity. 
Physician should adhere to the Endocrine Society20 
and Institute of Medicine21 recommendations in 
correcting the VDD and in maintenance doses.  
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